Rosane Vianna-Jorge et al.
Clinical pharmacology and therapeutics, 76(1), 18-26 (2004-07-02)
Cytochrome P450 (CYP) 2C9, the product of the polymorphic gene CYP2C9, provides the major catabolic pathway for several anti-inflammatory drugs, including tenoxicam. Our objectives were (1) to determine the frequency of 2 common CYP2C9 variant alleles (*2 and *3) in